VCS, recently approved, modified Tacrolimus molecule: -no impact on MPA when used in combo -flat dosing -improving lipid profile (vs CsA) -reduces DM risk (vs TAC) Drs. @alvinwellsmd and Fleischmann #RWCS2021 #RWCS @RheumNow @RWCSmtg https://t.co/238ZkJKhQ5